NovoCure Limited (NVCR)
NMS · Medical Devices
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Peers in Medical Devices
All in industry →Abbott Laboratories
Stryker Corporation
Medtronic plc
Boston Scientific Corporation
Edwards Lifesciences Corporation
GE HealthCare Technologies Inc.
Koninklijke Philips N.V.
DexCom, Inc.
STERIS plc
Zimmer Biomet Holdings, Inc.
Recent press releases
April 2026
NovoCure seeks shareholder vote on 9 million shares for incentives
# 📰 What This Document Is This document is a Definitive Proxy Statement (DEF 14A). Think of it as a comprehensive instruction manual for the upcoming Annual General Meeting of Shareholders. This statement is required by the SEC and provides shareholders with all the necessary information needed to
SEC filings
All filings →Insider trades
All insider trades →NovoCure Limited has no reported insider trades in the last 90 days.